iBio, Inc. (IBIO)
| Market Cap | 82.31M +384.6% |
| Revenue (ttm) | 100,000 -75.0% |
| Net Income | -33.04M |
| EPS | -0.32 |
| Shares Out | 64.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 445,357 |
| Open | 1.260 |
| Previous Close | 1.250 |
| Day's Range | 1.240 - 1.300 |
| 52-Week Range | 0.771 - 3.820 |
| Beta | 1.29 |
| Analysts | Strong Buy |
| Price Target | 5.69 (+344.53%) |
| Earnings Date | Aug 28, 2026 |
About IBIO
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company’s technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area... [Read more]
Financial Performance
In fiscal year 2026, iBio, Inc.'s revenue was $100,000, a decrease of -75.00% compared to the previous year's $400,000. Losses were -$33.04 million, 79.8% more than in 2025.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for IBIO stock is "Strong Buy." The 12-month stock price target is $5.69, which is an increase of 344.53% from the latest price.
News
iBio initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of iBio (IBIO) with a Buy rating and $7 price target The firm believes IBIO-610’s activin E antibody “looks promising.” The drug addressesa next-generation obesity, ...
iBio, Inc. Transcript: Wells Fargo 21st Annual Healthcare Conference
The discussion highlighted a robust pipeline of long-acting antibodies for obesity and related diseases, with a focus on quality weight loss and muscle preservation. Key assets include a unique Activin E antibody and a myostatin-targeting molecule, both leveraging advanced discovery technologies. Major clinical milestones are expected in the next 12 months.
iBio, Inc. Proxy statement: Proxy filing
iBio, Inc. filed a proxy statement on September 4, 2026, providing details for shareholder voting and corporate governance matters.
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulm...
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmo...
iBio, Inc. Annual report: Q4 2026
iBio, Inc. has published its Q4 2026 annual report on August 28, 2026.
iBio, Inc. Earnings release: Q4 2026
iBio, Inc. released its Q4 2026 earnings on August 28, 2026, summarizing the period's financial results.
iBio, Inc. Proxy statement: Proxy filing
iBio, Inc. filed a proxy statement on August 20, 2026, providing details for shareholder voting and corporate governance matters.
iBio appoints Molly Carr as chief medical officer
iBio (IBIO) announced the appointment of Molly Carr as chief medical officer as the company advances its clinical-stage cardiometabolic pipeline. Most recently, she served as clinical head and associa...
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary dis...
iBio announces new preclinical data from IBIO-610 study
iBio (IBIO) announced new preclinical data from its obese non-human primate, or NHP, study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate. Following a single dose of IB...
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach
iBio initiated with an Outperform at Raymond James
Raymond James initiated coverage of iBio (IBIO) with an Outperform rating and $5 price target iBio’s first antibody, IBIO-600, recently entered the clinic for obesity and the firm sees IBIO-610…
iBio, Inc. Transcript: Jefferies Global Healthcare Conference 2026
The portfolio targets obesity and related diseases post-GLP-1, focusing on muscle preservation, fat-specific weight loss, and weight maintenance. Lead programs are advancing through clinical milestones, leveraging unique antibody approaches for efficacy, safety, and scalability.
iBio to Participate in Upcoming Healthcare Investor Conferences
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases,...
iBio doses first participant in IBIO-600 trial
iBio (IBIO) announced the dosing of the first participant in its Phase 1 clinical trial of IBIO-600, the company’s most advanced obesity and cardiometabolic asset and its first program to…
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition
iBio, Inc. Slides: Corporate presentation
iBio, Inc. has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
iBio reports Q3 EPS (7c), consensus (6c)
“This last quarter was marked by significant advancement across our full pipeline. Most importantly, we received the clearance to enter the clinic with IBIO (IBIO)-600, which we believe has best-in-cl...
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
Received regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into pulmonary hypertension associated with heart failure with pr...
iBio, Inc. Earnings release: Q3 2026
iBio, Inc. released its Q3 2026 earnings on May 12, 2026, summarizing the period's financial results.
iBio, Inc. Quarterly report: Q3 2026
iBio, Inc. has published its Q3 2026 quarterly earnings report on May 12, 2026.
iBio, Inc. Transcript: Status update
AI-driven integration with experimental validation accelerates antibody drug discovery, enabling rapid clinic approval and overcoming immune tolerance for challenging targets. Generative models produce compact, functional antigen mimics, and future innovation is expected from simultaneous engineering of both antibody and antigen.
iBio receives regulatory clearance to initiate IBIO-600 trial in Australia
iBio (IBIO) announced IBIO-600 has received clinical trial notification acknowledgement from Australia’s Therapeutic Goods Administration and ethics approval from a Human Research Ethics Committee, en...
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First participants expected to be dosed in 2Q 2026 SAN ...